Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
2.
Tumori ; 106(6): NP63-NP66, 2020 Dec.
Article de Anglais | MEDLINE | ID: mdl-32912066

RÉSUMÉ

INTRODUCTION: Oligometastatic disease has emerged as an intermediate state between localized and systemic cancer. Improvements in diagnostic modalities such as functional imaging allow a greater frequency of oligometastases diagnosis. Patients with selected oligometastatic epithelial ovarian carcinoma (EOC) may be treated with metastasis-directed stereotactic body radiotherapy (SBRT) rather than chemotherapy. CASE DESCRIPTION: We describe a 58-year-old woman who underwent surgery and chemotherapy for an EOC. The patient underwent 3 chemotherapy lines for recurrence of disease, but had allergic reactions and serious hematologic toxicity. During follow-up, lymph node oligometastases were diagnosed and treated with repeated SBRT because the patient refused further chemotherapy. No side effects were observed after each course of SBRT and the patient obtained complete response of all irradiated sites. CONCLUSIONS: SBRT is a promising treatment approach for recurrent oligometastatic EOC with a high control rate and irrelevant iatrogenic toxicity. The possibility to repeat SBRT courses when new oligometastases are encountered in other sites resulted in an adequate long-term palliation approach.


Sujet(s)
Tumeurs de l'ovaire/anatomopathologie , Tumeurs de l'ovaire/thérapie , Soins palliatifs , Biopsie , Femelle , Humains , Métastase lymphatique , Adulte d'âge moyen , Stadification tumorale , Tumeurs de l'ovaire/imagerie diagnostique , Tumeurs de l'ovaire/radiothérapie , Soins palliatifs/méthodes , Tomographie par émission de positons couplée à la tomodensitométrie , Radiochirurgie/effets indésirables , Radiochirurgie/méthodes
3.
Q J Nucl Med Mol Imaging ; 60(4): 397-403, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-25017896

RÉSUMÉ

BACKGROUND: Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake. METHODS: [18F]FCH PET/CT was performed in 102 surgically treated patients with suspected recurrence (PSA increase >0.2 ng/mL) of prostate cancer, divided in two groups: under HT (N.=54) and without HT (N.=48) at the time of PET scanning. PET/CT was carried out by an integrated system (Biograph 6, CTI/Siemens, Knoxville, TN, USA) intravenously by administering 4.1 MBq/kg of [18F]FCH to each patient; images were acquired 60 minutes later. RESULTS: On the total number of patients, 66 were found to be true positives (TP), 9 false positives (FP), 5 false negatives (FN) and 22 true negatives (TN), sensitivity to [18F]FCH PET/CT was 93%, specificity 71%, accuracy 86%, positive predictive value (PPV) 88%, negative predictive value (NPV) 81%. In the 54 patients under HT, 38 were TP, 6 FP, 3 FN and 7 TN, sensitivity was 93%, specificity 54%, accuracy 83%, PPV 86% and NPV was 70%. In the 48 patients receiving no HT, 28 were TP, 3 FP, 2 FN and 15 TN, sensitivity was 93%, specificity 83%, accuracy 90%, PPV 90% and NPV 88%. A χ2 test showed that sensitivity, accuracy and PPV did not differ among patients with and without HT, while specificity and NPV were significantly lower (P<0.001) in HT treated patients. CONCLUSIONS: Sensitivity, accuracy and PPV were similar in patients with and without HT. Specificity and NPV were reduced in patients under HT, but further data are necessary to support if this reduction is casual or related to therapy and it could be confirmed in a larger series of patients.


Sujet(s)
Choline/analogues et dérivés , Hormones/usage thérapeutique , Tomographie par émission de positons , Tumeurs de la prostate/imagerie diagnostique , Tumeurs de la prostate/métabolisme , Sujet âgé , Sujet âgé de 80 ans ou plus , Transport biologique/effets des médicaments et des substances chimiques , Choline/métabolisme , Hormones/pharmacologie , Humains , Mâle , Adulte d'âge moyen , Tumeurs de la prostate/traitement médicamenteux , Tumeurs de la prostate/anatomopathologie , Récidive , Études rétrospectives
4.
Tumori ; 101(1): e21-3, 2015 Mar 20.
Article de Anglais | MEDLINE | ID: mdl-25702663

RÉSUMÉ

Computed tomography and magnetic resonance imaging detected an isolated adrenal lesion in an elderly man with high-risk prostate cancer who was undergoing radiotherapy (RT) and hormonal therapy (HT). When prostate-specific antigen (PSA) was 31.66 ng/mL, the lesion was not identified as a metastasis by 18F-choline positron emission tomography/computed tomography (18F-choline-PET/CT). When PSA was over 100 ng/mL, 18F-choline-PET/CT diagnosed the malignancy. After adrenalectomy, PSA returned to normal, and stable disease remission was obtained. This case suggests that atypical metastasis may be underdiagnosed.


Sujet(s)
Adénocarcinome/diagnostic , Adénocarcinome/secondaire , Tumeurs de la surrénale/diagnostic , Tumeurs de la surrénale/secondaire , Surrénalectomie , Marqueurs biologiques tumoraux/sang , Choline/analogues et dérivés , Radio-isotopes du fluor , Tomographie par émission de positons , Antigène spécifique de la prostate/sang , Tumeurs de la prostate/anatomopathologie , Adénocarcinome/chirurgie , Tumeurs de la surrénale/chirurgie , Sujet âgé , Antinéoplasiques hormonaux/usage thérapeutique , Traitement médicamenteux adjuvant , Humains , Immunohistochimie , Imagerie par résonance magnétique , Mâle , Imagerie multimodale/méthodes , Seconde tumeur primitive/diagnostic , Tomographie par émission de positons/méthodes , Tumeurs de la prostate/sang , Tumeurs de la prostate/thérapie , Radiothérapie adjuvante , Tomodensitométrie
5.
Rheumatol Int ; 32(5): 1367-70, 2012 May.
Article de Anglais | MEDLINE | ID: mdl-20238219

RÉSUMÉ

A 62-year-old man presented with a 2-month history of increasing pain in the left hip. Magnetic resonance imaging (MRI) showed bone marrow edema (BME) of the left femur, dual energy X-ray absorptiometry (DXA) showed osteopenia at the same level, whereas pelvis X-rays failed to show any objective findings. After ruling out other possible causes of BME such as aseptic osteonecrosis, infectious arthritis, primary or metastatic malignancy, tuberculosis, osteomyelitis, rheumatoid arthritis, and seronegative spondyloarthropathies, a diagnosis of transient osteoporosis of the hip (TOH) was made, and treatment with teriparatide at a daily dose of 20 µg was started and continued for 4 weeks. Disappearance of the symptoms and normalization of MRI were obtained.


Sujet(s)
Agents de maintien de la densité osseuse/usage thérapeutique , Articulation de la hanche/effets des médicaments et des substances chimiques , Ostéoporose/traitement médicamenteux , Tériparatide/usage thérapeutique , Absorptiométrie photonique , Arthralgie/étiologie , Densité osseuse/effets des médicaments et des substances chimiques , Maladies de la moelle osseuse/étiologie , Oedème/étiologie , Articulation de la hanche/imagerie diagnostique , Articulation de la hanche/anatomopathologie , Humains , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Imagerie multimodale , Ostéoporose/complications , Ostéoporose/diagnostic , Tomographie par émission de positons , Valeur prédictive des tests , Facteurs temps , Tomodensitométrie , Résultat thérapeutique
6.
Eur J Nucl Med Mol Imaging ; 32(9): 1011-7, 2005 Sep.
Article de Anglais | MEDLINE | ID: mdl-15895228

RÉSUMÉ

PURPOSE: The purpose of this study was to investigate the added value of co-registered fusion imaging using a hybrid system in patients with lymphoma. METHODS: Twenty-four lymphoma patients underwent (67)Ga-SPECT/CT using a hybrid tomograph consisting of a dual-head, variable-angle gamma camera and a low-dose X-ray tube. Results were compared with those of SPECT alone. RESULTS: Forty-five lesions were identified by SPECT alone, while 49 were detected by SPECT/CT. Forty out of the 45 lesions observed on SPECT were confirmed as lymphoma, but five were due to other causes (thoracic aorta blood pool activity, sialoadenitis in the submandibular gland, bowel activity, rib fracture and bone marrow activation due to radiotherapy). SPECT/CT identified nine more neoplastic lesions compared with SPECT alone: four areas of radiopharmaceutical accumulation were observed in para-aortic lymph nodes, three in the spleen, one in the liver and one in para-iliac lymph nodes. In five cases, SPECT/CT provided additional anatomical information over SPECT alone. In four patients, four large areas of (67)Ga uptake (one mediastinal, two supraclavicular and one para-aortic) were better characterised; in one subject uptake was localised in the seventh thoracic vertebra only by SPECT/CT. Hybrid imaging provided additional data in 13 patients (54.2%), thus inducing oncologists to reconsider the therapeutic approach in eight subjects (33.2%): unnecessary treatment was avoided in four (16.6%) while therapy was altered in another four (16.6%). CONCLUSION: SPECT/CT hybrid system is able to provide information not obtained by SPECT alone. It allows the anatomical localisation of lymphoma and physiological radiopharmaceutical uptake, facilitates the diagnosis of tumours located in the abdomen (subdiaphragmatic lesions) and provides information that may cause a change in therapeutic strategy.


Sujet(s)
Amélioration d'image/méthodes , Lymphomes/diagnostic , Lymphomes/thérapie , Technique de soustraction , Tomographie par émission monophotonique/méthodes , Tomodensitométrie/méthodes , Adolescent , Adulte , Citrates , Femelle , Gallium , Humains , Mâle , Adulte d'âge moyen , Pronostic , Radiopharmaceutiques , Reproductibilité des résultats , Sensibilité et spécificité , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...